Market Minds Advisory
Liver Fibrosis Treatment Market

Liver Fibrosis Treatment Market: First-Approval Commercialization and GLP-1 Convergence Dynamics

The first regulatory-approved fibrosis-specific therapy has turned a decade of failed trials into a genuine commercial category almost overnight, pulling GLP-1 developers and diagnostic companies into a race most were not positioned for.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.4BMarket Size 2025
2036 FORECAST VALUE$7.4BBase Case , 2026 to 2036
CAGR 2026 TO 203616.4 %Bull 17.6% / Bear 15.1%
INCREMENTAL OPPORTUNITY$5.8BNet 10- year value creation
EXPANSION MULTIPLE4.57x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Liver fibrosis treatment is transforming from a category defined by repeated clinical trial failure into a genuine commercial market as the first regulatory-approved fibrosis-specific therapy reaches patients, a shift that rewards companies with completed outcomes evidence over those still running early-stage trials.
GLP-1 and GIP receptor agonist therapies form the fastest-growing segment as diabetes and obesity drugs originally developed for metabolic indications demonstrate measurable liver fibrosis improvement in expanding clinical evidence. North America anchors the deepest commercial concentration, reflecting the region's sole completed regulatory approval pathway to date and the country's uniquely developed reimbursement infrastructure for newly launched specialty therapeutics, a combination other regions still cannot fully replicate at comparable commercial scale today.
Madrigal Pharmaceuticals and Novo Nordisk set the commercial benchmark through first-mover regulatory approval and massive manufacturing and distribution scale respectively, while a fragmented tier of clinical-stage developers competes on trial rigor and mechanism differentiation. Expanding regulatory approval activity and growing diagnostic-driven patient identification are both reshaping which companies capture treatment volume as validated clinical outcomes increasingly outweigh pipeline promise alone across the category. Smaller developers increasingly form licensing partnerships to remain competitive against this pressure.
Market Definition
The liver fibrosis treatment market covers pharmaceutical therapies used to treat, slow, or reverse liver fibrosis associated with metabolic dysfunction-associated steatohepatitis and related chronic liver conditions, including thyroid hormone receptor beta agonists, GLP-1 and GIP receptor agonists, FGF21 analogs, and antifibrotic small molecules. It spans regulatory-approved therapies and late-stage pipeline candidates sold or administered through specialty pharmacy and hepatology practice channels. Liver transplantation, unrelated viral hepatitis antiviral therapies, and general weight management products without demonstrated fibrosis benefit are excluded from this scope.
Base Year Value
$1.4B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
16.4% base case. Bull 17.6%. Bear 15.1%.
Fastest Growth Segment
GLP-1/GIP Receptor Agonist Therapies: 24.8% CAGR
Fastest Growth Country
China: 19.8% CAGR
Fastest Growth Region
South Asia and Pacific: 18.4% CAGR
Largest Region
North America: 38% of 2025 global value
Market Leaders
Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Akero Therapeutics, 89bio. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Liver Fibrosis Treatment Market Forecast Scenarios

liver-fibrosis-treatment-market-size-forecast-scenario-1787305938869
Liver fibrosis treatment demand grew rapidly across 2020 to 2025 as clinical trial evidence accumulated across multiple mechanism classes, then accelerated sharply following the category's first regulatory approval that validated fibrosis as a genuinely treatable clinical endpoint. The market grew at an estimated 15.2% historical CAGR across the period, reflecting a genuine step change once the first approved therapy moved from trial promise into commercial reality.
The base case assumes regulatory approval activity continues expanding through 2030 as additional mechanism classes complete pivotal trials, non-invasive diagnostic adoption keeps improving patient identification ahead of irreversible cirrhosis progression, and payer coverage decisions keep broadening as real-world outcomes evidence accumulates. Together these three mechanisms support a 16.4% forecast CAGR, with thyroid hormone receptor beta agonist therapy remaining the volume anchor even as GLP-1 and FGF21 formats capture growing value share each year worldwide.
The bull case centers on faster-than-expected GLP-1 label expansion into fibrosis indications that pushes prescribing volume well ahead of current commercialization timelines. The bear case centers on renewed clinical evidence scrutiny following disappointing pivotal trial results in a major mechanism class, which would slow payer coverage decisions and compress developer valuations across the industry for several years as consolidation accelerates.

First-Approval Commercialization and Mechanism Convergence Dynamics

Liver fibrosis treatment sits at the intersection of hepatology clinical science and metabolic disease drug development, since fibrosis reversal requires demonstrating a genuinely novel clinical endpoint that regulators only recently accepted as sufficient for approval after years of prior program failures across the industry. That split has kept the vendor base divided between the category's sole approved-therapy company and a broad tier of clinical-stage developers still pursuing regulatory va
TOP 5 CONCENTRATION56%share held by leading five liver fibrosis treatment companies
AVERAGE ANNUAL TREATMENT COST$47,400 per patienttypical annual cost across approved fibrosis-specific therapy options
LEADING COUNTRY SHAREUnited States, 31%share of global liver fibrosis treatment commercial revenue
DIAGNOSED PATIENT TREATMENT RATE14% of diagnosed patientsshare of diagnosed fibrosis patients currently receiving therapy
CLINICAL TRIAL PIPELINE DEPTH38 candidates in trialstypical number of fibrosis-specific candidates in active clinical trials
PAYER COVERAGE RATE52% of major payersshare of major payers covering the approved fibrosis therapy
Commercially, the market splits between a newly established thyroid hormone receptor beta agonist base sold through specialty pharmacy and hepatology practice relationships built over less than two years of commercial availability, and a much larger pipeline of GLP-1, FGF21, and combination candidates still advancing through late-stage trials. Diagnostic-driven patient identification rounds out demand with screening-linked purchasing tied to non-invasive fibrosis staging adoption.
Over the next decade, clinical outcomes depth and diagnostic-linked patient identification will matter more than raw pipeline breadth alone, since prescribers increasingly select therapies based on demonstrated fibrosis regression data rather than mechanism novelty alone. Companies that expand outcomes evidence into mid-tier hepatology practice relationships fastest stand to capture a widening share of a market that regulatory validation is reshaping as much as raw diagnosed population growth is.
"For a decade this was the graveyard category, where promising drugs went to fail phase three. Now it's the opposite problem: too many companies racing into a market that has exactly one approved product and a diagnostic pathway most hepatologists still aren't using consistently."
Director, Hepatology and Metabolic Disease Therapeutics Practice · MMA Healthcar

Market Trends

GLP-1 Developers Pursue Fibrosis Label Expansion

Major GLP-1 and GIP receptor agonist developers are increasingly pursuing dedicated fibrosis indication trials building on metabolic drugs already approved for diabetes and obesity, seeking to expand labeling beyond weight management into a genuinely differentiated liver disease claim. Novo Nordisk and Eli Lilly have both expanded fibrosis-specific trial investment since 2023, targeting hepatologists who want metabolic and fibrosis benefit within a single therapy. Smaller developers are following this pathway more cautiously, constrained by the trial investment required relative to established GLP-1 manufacturing scale, but label expansion activity is broadening steadily each year across major regulatory markets worldwide.
Market Impact: Adds 6% annual at-risk population g

Non-Invasive Diagnostic Adoption Expands Treatable Population

Non-invasive fibrosis staging technologies including elastography and blood-based biomarker panels are increasingly replacing invasive liver biopsy as the primary diagnostic pathway, expanding the identified patient population eligible for treatment well beyond historical biopsy-limited diagnosis rates. Major diagnostic companies have expanded non-invasive staging platform investment since 2023, targeting primary care and endocrinology practices that previously lacked convenient referral pathways into hepatology. This diagnostic shift is broadening treatable population identification steadily each year across major healthcare markets worldwide. Health systems increasingly view diagnostic pathway investment as a critical patient identification priority. today.
Market Impact: Cuts regulatory uncertainty by 30%

Market Opportunities and Growth Drivers

Rising Metabolic Dysfunction Prevalence Expands Patient Population

Global obesity and type two diabetes prevalence continues rising each year, sustaining long-term growth in the population at risk for metabolic dysfunction-associated liver fibrosis regardless of near-term payer coverage cycles in any single market. This prevalence growth provides a durable baseline demand floor beneath the faster-growing diagnostic identification trend layered on top of it, since underlying metabolic disease burden continues expanding independent of specific treatment mechanism choices. Health systems increasingly prioritize metabolic disease screening as a standard primary care component. Companies with strong metabolic disease awareness campaigns increasingly capture this expanding demand first.
Market Impact: Excludes 68% of eligible patients

Regulatory Precedent Accelerates Subsequent Approval Pathways

The category's first regulatory approval has established a clinical endpoint precedent that subsequent developers can now reference when designing pivotal trials, meaningfully reducing regulatory uncertainty that historically discouraged investment in fibrosis-specific drug development programs. This precedent effect sustains long-term pipeline investment growth regardless of near-term individual trial outcomes, since the approval pathway itself is now substantially de-risked for well-designed programs. Investors increasingly view fibrosis-specific programs as a credible therapeutic category worth continued funding. Regulatory bodies increasingly reference this precedent when evaluating subsequent approval applications across the category. That precedent shortens development timelines meaningfully.
Market Impact: Limits access for 44% patients

Market Restraints and Challenges

Diagnostic Pathway Fragmentation Limits Patient Identification

Non-invasive fibrosis staging adoption remains inconsistent across primary care and endocrinology practices that see the largest share of at-risk metabolic disease patients, meaning many patients who would benefit from treatment never receive the staging workup needed to establish treatment eligibility in the first place. This fragmentation is most pronounced outside major academic hepatology centers, where primary care physicians often lack established referral pathways or awareness of newly available fibrosis-specific therapy options. Companies and health systems are responding by funding physician education programs and diagnostic pathway partnerships, though achieving broad diagnostic consistency will take considerable additional time.
Market Impact: Adds $18,000 per expanded label pat

High Treatment Cost Constrains Broader Payer Access

Annual treatment costs for the category's approved and pipeline fibrosis-specific therapies remain substantially higher than many payers historically budgeted for a chronic metabolic condition, creating access friction even among patients who have completed diagnostic staging and would otherwise qualify for treatment under current labeling. This constraint is most pronounced in markets without comprehensive specialty pharmacy coverage mandates, leaving many diagnosed patients without practical access despite meeting clinical criteria. Companies are responding by expanding patient assistance programs and pursuing value-based contract structures tied to measured fibrosis outcomes. today. Investors are watching this dynamic closely.
Market Impact: Adds 22% more diagnosed patients an
3 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Liver fibrosis therapies segment by mechanism of action, the classification prescribers and payers use to set reimbursement pathway, evidence requirements, and pricing tier, since thyroid receptor, GLP-1, and antifibrotic buyers each negotiate coverage under distinct clinical terms. Vendors price each category differently depending on evidence depth and mechanism novelty involved across the industry. today.
liver-fibrosis-treatment-market-market-share-analysis-1787305939405

GLP-1/GIP Receptor Agonist Therapies

GLP-1 and GIP receptor agonist therapies form the fastest-growing segment as diabetes and obesity drugs originally developed for metabolic indications demonstrate measurable liver fibrosis improvement in expanding clinical evidence across multiple large trials. Novo Nordisk and Eli Lilly have both expanded fibrosis-specific trial investment since 2023, targeting hepatologists who want a therapy addressing both metabolic and liver disease within a single prescription. Companies that secure fibrosis label expansion are capturing prescribing volume from competitors that lack comparable dual-indication evidence, an advantage that compounds as more prescribers standardize around a smaller set of trusted dual-benefit therapies. If label expansion continues at the current pace, this segment could approach a meaningful share of total category value within the next several years.
CAGR 24.8%

FGF21 Analog Therapies

FGF21 analog therapies form the second-fastest segment as clinical-stage developers advance a mechanism class showing particularly strong fibrosis regression data in mid-stage trials, distinct from the metabolic-focused mechanisms driving other segments. Akero Therapeutics and 89bio have both expanded pivotal trial investment since 2023, targeting hepatologists who want the strongest available fibrosis-specific regression evidence for advanced-stage patients. Companies that complete pivotal trials early are capturing prescriber attention from competitors still in earlier development phases, an advantage that compounds as more hepatologists follow emerging trial readouts closely. This segment increasingly serves patients with more advanced fibrosis staging seeking maximum regression potential. Payers increasingly view this segment as a durable long-term differentiator worth close monitoring.
CAGR 19.6%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Liver fibrosis treatment commercial activity concentrates where regulatory approval and specialty reimbursement infrastructure are most developed, even though underlying at-risk metabolic disease population runs highest in regions still building the diagnostic and coverage infrastructure needed to convert that population into treated patients. particularly across major research and reimbursement markets worldwide.

North America

The United States accounts for the overwhelming majority of North America's liver fibrosis treatment commercial value, reflecting the region's sole completed regulatory approval pathway to date and uniquely developed specialty pharmacy reimbursement infrastructure supporting broad early commercial access, a combination that pushes the region well above its default commercial share band, reflecting a genuine first-mover regulatory concentration rather than a default geographic assumption. Canada contributes a smaller but meaningful share through its established hepatology referral infrastructure. Diagnostic-driven patient identification runs meaningfully ahead of the global average across most large academic hepatology centers in the region. Venture funding concentration continues reinforcing this advantage each year across major biotechnology hubs nationwide. Investors continue tracking this dynamic closely.
Share: 38% | CAGR: 15.6% (2026 to 2036)

Western Europe

Germany, the United Kingdom, and France together anchor Western Europe's liver fibrosis treatment demand, reflecting well-established national health system hepatology infrastructure and comparatively cautious regulatory evaluation of newly approved therapies relative to United States commercialization pathways. Regulatory review timelines for fibrosis-specific therapies across the European Union proceed more deliberately than the accelerated United States pathway, delaying broad regional access somewhat. Smaller Western European markets rely more heavily on centralized reference hepatology centers rather than distributed specialty care networks, concentrating treatment volume at fewer high-throughput facilities. Regional diagnostic pathway investment continues expanding across national health systems each year. Regional diagnostic pathway partnerships continue expanding gradually across national health system infrastructure investment.
Share: 21% | CAGR: 14.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
liver-fibrosis-treatment-market-country-cagr-analysis-1787305939934

Where Commercial Value Concentrates Next

Revenue growth in liver fibrosis treatment increasingly depends on capturing GLP-1 label expansion, diagnostic-driven patient identification, and hepatology practice partnerships rather than raw approved-molecule volume alone, since regulatory validation, not raw pipeline breadth, is reshaping where value concentrates across the industry today. The levers below outline where that value is concentrating fastest across the industry.

Completing Pivotal Fibrosis Regression Trials Ahead Of Peers

Companies completing pivotal fibrosis regression trials ahead of competitors are capturing hepatologist prescribing attention that earlier-phase rivals cannot access given the category's demand for genuine regulatory validation. Running a competitive pivotal trial typically costs $150 million to $320 million in clinical operations, patient recruitment, and long-term biopsy or non-invasive endpoint follow-up investment. Companies without completed trials increasingly lose prescriber mindshare to better-evidenced competitors offering proven regression data sooner, and that gap widens each successive year as coverage criteria tighten around completed evidence. Adoption continues broadening steadily as more trials reach completion across the industry.
Market Impact: Costs $150 to $320 million to fully

Building Non-Invasive Diagnostic Referral Partnerships Now

Companies building dedicated non-invasive diagnostic referral partnerships with primary care and endocrinology practices are capturing patient identification volume that hepatology-only referral pathways cannot match given how few patients reach specialist care before advanced fibrosis staging. Developing competitive referral infrastructure typically costs $12 million to $28 million in diagnostic partnership development, physician education, and referral platform investment. Companies with superior referral infrastructure increasingly win earlier patient identification from competitors dependent on late-stage specialist referral alone. Adoption continues broadening steadily as more practices seek coordinated referral pathways. That advantage compounds each successive year.
Market Impact: Costs $12 to $28 million to fully b

Securing Large Health System Treatment Protocols

Companies securing dedicated treatment protocol partnerships with large integrated health systems are capturing volume growth that transactional individual prescriber relationships cannot match on scale and long-term diagnostic-to-treatment pathway commitment. These partnerships typically carry a 20 to 30% margin premium given the coordinated diagnostic and treatment workflow health systems value. Companies able to demonstrate reliable fibrosis outcomes increasingly win these partnerships over less-prepared competitors seeking similar health system access. Adoption continues broadening steadily as more health systems seek coordinated treatment protocols. That advantage compounds each successive year as more systems consolidate treatment vendor relationships.
Market Impact: Commands a 20 to 30% margin premium

Investing In Combination Regimen Development Capability

Companies investing in combination regimen development capability are positioned to capture treatment volume from patients with advanced fibrosis who may benefit from complementary mechanisms addressing both metabolic drivers and direct fibrotic tissue remodeling within a coordinated regimen. Developing competitive combination capability typically costs $60 million to $140 million in clinical trial design, regulatory submission, and manufacturing coordination investment. Companies with strong combination capability increasingly win advanced-stage patient prescribing from competitors offering only single-mechanism alternatives. Adoption continues broadening steadily as more prescribers seek combination regimen options. That advantage compounds each successive year.
Market Impact: Costs $60 to $140 million to fully

Who Controls the Margin Pool

The top five vendors hold an estimated 56% of global liver fibrosis treatment revenue, a meaningful concentration reflecting the category's extreme early-stage nature where only a handful of companies have completed regulatory validation or hold sufficient manufacturing scale to compete credibly. Madrigal Pharmaceuticals and Novo Nordisk lead on first-mover approval status and manufacturing and distribution scale respectively, while a fragmented tier of clinical-stage developers competes on tria
Current competitive activity centers on three fronts. Pivotal trial completion is opening a new front for developers willing to invest ahead of confirmed regulatory approval. Diagnostic referral partnership development is becoming increasingly important as companies compete on earlier patient identification beyond hepatology-only referral pathways. And several mid-sized developers are pursuing large health system treatment protocol partnerships to differentiate beyond commoditized individual prescriber sales.

Emerging pressure comes from clinical-stage developers advancing FGF21 and combination mechanism candidates as they partner with academic medical centers and contract research organizations, though matching Madrigal Pharmaceuticals or Novo Nordisk's regulatory head start and manufacturing scale remains years away for most. If these challengers close that gap, expect share to shift within specific mechanism categories first, before pressure reaches the largest established incumbents.
liver-fibrosis-treatment-market-company-positioning-matrix-1787305940460

Competitive Moat and Risk Dimensions

MADRIGAL PHARMACEUTICALS INC.

Moat: First-Mover FDA-Approved THR-Beta Therapy

Madrigal holds the category's first and only completed regulatory approval, built through years of dedicated clinical trial investment establishing the fibrosis regression endpoint precedent that subsequent developers now reference. That first-mover position gives Madrigal a durable commercial head start that competitors still completing pivotal trials cannot quickly replicate, even as new entrants continue advancing through late-stage development.
MADRIGAL PHARMACEUTICALS INC.

Risk: Single-Product Revenue Concentration Risk

Madrigal's revenue depends almost entirely on its single approved therapy, creating meaningful exposure to competitive entry from GLP-1 and FGF21 developers whose broader pipelines and manufacturing scale could erode its early commercial advantage over time. If competing mechanisms demonstrate comparable or superior efficacy, Madrigal risks losing its narrow first-mover window faster than its limited pipeline diversification can offset.
NOVO NORDISK A/S

Moat: Massive GLP-1 Manufacturing Scale

Novo Nordisk maintains massive existing GLP-1 manufacturing and global distribution infrastructure built through years of diabetes and obesity therapy commercialization, giving it a manufacturing and prescriber relationship advantage that fibrosis-specific developers without comparable scale cannot easily match. That existing infrastructure lets Novo Nordisk pursue fibrosis label expansion with substantially lower incremental commercial investment than new market entrants.
NOVO NORDISK A/S

Risk: Manufacturing Capacity Constraints Limit Supply

Novo Nordisk's existing GLP-1 manufacturing capacity remains constrained by surging diabetes and obesity demand, creating supply allocation tension that could limit how aggressively the company can pursue fibrosis-specific volume without compromising its core metabolic disease franchise. If capacity constraints persist, Novo Nordisk risks ceding fibrosis-specific prescribing share to competitors with more available dedicated manufacturing capacity.

Players Tracked

Prominent Players

Madrigal Pharmaceuticals Inc.
Novo Nordisk A/S
Eli Lilly and Company
Akero Therapeutics Inc.
89bio Inc.

Other Key Players

Boehringer Ingelheim GmbH
Pfizer Inc.
Novartis AG
Gilead Sciences Inc.
Intercept Pharmaceuticals Inc.
Viking Therapeutics Inc.
Sagimet Biosciences Inc.
Terns Pharmaceuticals Inc.
Galmed Pharmaceuticals Ltd.
Genfit S.A.
Inventiva S.A.
NorthSea Therapeutics B.V.
Zydus Lifesciences Limited
Astellas Pharma Inc.
Regeneron Pharmaceuticals Inc.

Recent Developments

MAY 2025

Madrigal Pharmaceuticals Publishes Extended Real-World Outcomes Data

Madrigal Pharmaceuticals published extended real-world outcomes data demonstrating sustained fibrosis improvement among treated patients followed across an expanding multi-site patient population since commercial launch. Payers cited the publication when reviewing broader coverage decisions across several major health plans nationwide. Analysts expect similar publications from other qualified competitors soon.
Signal: Confirms real-world outcomes evidence rema
OCTOBER 2024

Novo Nordisk Advances Fibrosis Indication Pivotal Trial

Novo Nordisk advanced its dedicated liver fibrosis indication pivotal trial into late-stage enrollment, building on existing GLP-1 metabolic approval to pursue formal fibrosis labeling expansion across several affiliated development programs. The advancement followed years of earlier-phase biomarker and imaging endpoint data collection. Investors welcomed the advancement as a pipeline milestone.
Signal: Shows major metabolic disease developers p
JANUARY 2025

Akero Therapeutics Announces Positive Pivotal Trial Results

Akero Therapeutics announced positive pivotal trial results for its FGF21 analog candidate, demonstrating meaningful fibrosis regression among advanced-stage patients enrolled across multiple clinical trial sites. Similar pivotal readouts are expected across other qualified competitors over the coming year as trials mature. Investors welcomed the results as a meaningful validation signal.
Signal: Signals FGF21 analog mechanisms are becomi

Clinical Trial and Manufacturing Scale-Up Cost Pressure

Clinical trial execution and manufacturing scale-up infrastructure together account for roughly 48% of effective cost of goods for liver fibrosis treatment companies, given the extensive pivotal trial requirements and specialized biologics or small molecule manufacturing capacity needed to support commercial launch. Regulatory submission and post-marketing surveillance costs add a further meaningful share, particularly for companies pursuing first-in-class approval pathways.
Clinical trial and manufacturing scale-up costs rose meaningfully following 2023 intensifying competition for qualified trial sites and manufacturing capacity as multiple developers simultaneously advanced pivotal programs, with several companies reporting cost increases exceeding 24% in subsequent funding rounds before costs stabilized through 2024. Industry analyses have flagged pivotal trial execution as this market's single most capital-intensive input, more than manufacturing or regulatory costs combined. Several developers have flagged rising trial costs as an ongoing fundraising challenge.

Smaller clinical-stage developers without sustained venture funding absorbed the 2023 cost increases hardest, losing trial site access to larger competitors including Novo Nordisk and Eli Lilly that had already secured priority site relationships years in advance. Companies with secured multi-year funding weathered the cost increases far better than those dependent on near-term fundraising rounds, a resilience advantage that persists most sharply across smaller developers today.
liver-fibrosis-treatment-market-cost-volatility-analysis-1787305940655

Platform Trial Designs Reduce Per-Mechanism Cost

Developers increasingly design platform trials that generate evidence supporting multiple mechanism combinations simultaneously, reducing the incremental cost of expanding clinical evidence beyond a single initial therapy. This approach has helped several developers extend limited trial budgets across broader combination portfolios more efficiently. Several developers report significantly faster time-to-market using this shared platform approach. today.

Academic Medical Center Partnerships Lower Trial Costs

Developers increasingly partner with academic hepatology centers to access subsidized trial infrastructure and patient recruitment support, reducing the standalone capital burden that smaller companies would otherwise face running trials independently. This approach has helped several developers complete pivotal trials with meaningfully smaller funding rounds than would otherwise be required. Several developers report lower overall trial costs using this partnership model.

Contract Manufacturing Partnerships Reduce Capital Intensity

Several smaller developers are partnering with contract manufacturing organizations to access commercial-scale production capacity without building proprietary manufacturing infrastructure, reducing the capital intensity that would otherwise delay commercial launch timelines. This approach also provides flexibility to scale production as approval and demand materialize. Several developers report faster commercial launch timelines using this contract manufacturing approach.

Portfolio Architecture for Margin Defence

Liver fibrosis treatment portfolios span three margin tiers, from an early commodity-adjacent tier that barely exists yet given the category's nascency, through the currently dominant certified approved-therapy tier carrying substantial evidence-driven premiums, toward an emerging next-generation tier built around combination regimens and expanded indications still gaining share. Gross margin widens meaningfully at each tier as clinical evidence and mechanism differentiation increase, reflecting
The volume versus premium tension centers on trial and manufacturing investment allocation. Companies must choose between dedicating capital to high-margin combination and expanded-indication programs with growing but still-uncertain volume, or racing to complete pivotal trials that establish baseline approved-therapy revenue across a typical development cycle. Companies without spare capital increasingly favor pivotal trial completion where the category's core commercial opportunity still concentrates.

High-value margin pools concentrate in approved and near-approval therapies with completed pivotal trials, where evidence investment and regulatory validation keep competition thin and prescribers pay a substantial premium for proven fibrosis regression certainty. Early-stage pipeline candidates anchor investment activity but carry the highest risk and thinnest near-term revenue, leaving smaller developers fewer diversification options than larger integrated competitors.

Volume / Commodity-Adjacent Tier

Early-stage pipeline candidates and off-label metabolic therapies used before dedicated fibrosis approval, across most standard early-development programs worldwide. Limited commercial revenue keeps this tier defined mostly by development-stage investment rather than sales.
Gross Margin: 0-10%

Premium / Certified Tier

Regulatory-approved fibrosis-specific therapies sold under specialty pharmacy and payer contracts carrying substantial evidence-driven pricing power built through completed pivotal trial performance. Payers increasingly compare outcomes data before committing to a coverage decision.
Gross Margin: 58-72%

Sustainability / Regulatory / Next-Generation Tier

Combination regimen and expanded-indication therapies in active development, commanding premium pricing potential against limited proven alternatives as clinical evidence and manufacturing scale expand across major markets. Companies with the deepest clinical evidence and manufacturing scale capture most of this premium value today.
Gross Margin: 50-64%
liver-fibrosis-treatment-market-portfolio-architecture-1787305941158

High-value Sub-segments and Strategic Watch-out

GLP-1/GIP Receptor Agonist Therapies

Fastest-growing and highest long-term value pool as major metabolic developers pursue fibrosis label expansion under accumulating clinical evidence and existing manufacturing scale. Novo Nordisk and Eli Lilly are among those actively expanding trial investment today. That advantage compounds as more prescribers standardize around dual-benefit therapies each year.
Gross Margin: 56-70%

FGF21 Analog Therapies

High-value pool growing steadily as pivotal trial results demonstrate strong fibrosis regression, particularly across advanced-stage patients where regression demand has increased meaningfully since 2023. Akero Therapeutics and 89bio continue expanding capacity, reinforcing this segment's growth trajectory. Investors increasingly track pivotal readouts closely across this competitive mechanism category.
Gross Margin: 54-68%

Thyroid Hormone Receptor Beta Agonist Therapies

Steady volume core segment tied to the category's sole approved mechanism, carrying the strongest near-term margins given first-mover status but facing narrowing exclusivity as competing mechanisms approach approval. Madrigal Pharmaceuticals anchors most current commercial revenue today. This segment anchors baseline commercial revenue across the category currently.
Gross Margin: 58-72%

Diagnostic-Constrained Undiagnosed Patient Segment

Strategic watch-out segment facing a persistent identification ceiling as fragmented non-invasive diagnostic adoption leaves companies dependent on referral pathway buildout rather than guaranteed broad patient access nationwide. Companies serving this segment increasingly fund diagnostic partnerships to offset this gap. That ceiling persists until referral pathway investment fully matures.
Gross Margin: 20-32%

Recurring Chronic Specialty Prescription Relationship

Liver fibrosis treatment purchasing functions closer to a recurring annuity than a single transaction for diagnosed patients, since fibrosis is a chronic progressive condition requiring sustained treatment across years once a hepatologist establishes an initial therapy and monitoring relationship. Diagnostic staging events behave differently, occurring at discrete screening points rather than following any predictable purchasing schedule.
Adoption depth varies sharply by end-use vertical. Academic hepatology centers and large integrated health systems show the deepest engagement with newly approved and pipeline therapies, given dedicated specialist staff and comfort evaluating emerging clinical evidence, while general endocrinology and primary care practices adopt more slowly since specialized fibrosis staging investment rarely gets prioritized given comparatively low individual referral volume. That divide shapes where companies concentrate commercial and diagnostic partnership investment.

A generational shift is underway as younger hepatologists and endocrinologists, trained during the era of routine fibrosis-specific therapy availability, evaluate treatment options based on published regression evidence and diagnostic pathway sophistication rather than the prior decade of prescribing habits built around managing fibrosis with metabolic therapies alone. That openness gives evidence-forward companies a rare opening to win prescriber share in a category still actively forming its standard of care.
liver-fibrosis-treatment-market-end-use-penetration-index-1787305941650

Where MMA Sees The Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / PIVOTAL TRIAL INVESTMENT

Complete Pivotal Trials Before The Approval Window Narrows

Prescribers are increasingly requiring completed pivotal trial evidence before adopting a company as a genuine treatment option, and developers without adequate trial investment are losing prescriber attention to better-evidenced competitors as this shift accelerates. Trial investment requires substantial upfront capital but opens durable prescriber relationships that earlier-phase competitors cannot match once regulatory validation fully materializes. Developers waiting too long to complete pivotal evidence will find themselves racing to catch up against incumbents who invested years earlier, a gap that widens each quarter trial investment lags behind competitor programs already underway.
02 / DIAGNOSTIC PARTNERSHIP INVESTMENT

Build Diagnostic Referral Pathways Before Practices Standardize

Primary care and endocrinology practices have not universally committed to a single fibrosis diagnostic referral pathway, leaving a genuine opportunity for companies willing to fund referral infrastructure ahead of confirmed industry standardization trends. Waiting for referral standards to formally standardize risks missing the commercial differentiation window entirely once a preferred pathway forms across practice networks. The investment required is meaningful but positions early movers to capture a category growing faster than hepatology-only referral pathways today, a window that will not stay open indefinitely.
03 / HEALTH SYSTEM PARTNERSHIP DEVELOPMENT

Pursue Treatment Protocols Before Standards Of Care Solidify

Large integrated health system treatment protocol formation has repeatedly rewarded early-mover companies first, and companies without dedicated partnership strategies risk ceding this forming category to competitors who invest in coordinated treatment relationships earlier. Health system partnerships represent a meaningful growth opportunity even though individual prescriber sales currently drive most category revenue. Companies pursuing partnership development now, while the standard of care remains unsettled, protect volume against the next wave of competitors entering this rapidly forming category across most major regional health systems worldwide.
04 / REGIONAL ACCESS INVESTMENT

Prioritize South Asia and East Asia Access Investment Now

South Asia and Pacific and East Asia carry rapidly growing metabolic disease patient populations relative to their current commercial liver fibrosis treatment value, as diagnostic infrastructure and regulatory frameworks accelerate across India, China, and neighboring markets. Companies concentrating capacity expansion solely around legacy Western prescriber relationships risk ceding share in the regions where patient volume growth will be steepest through 2036. Early investment in regional diagnostic and distribution partnerships offers a meaningful head start over competitors still anchored entirely to legacy Western customer bases.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Liver Fibrosis Treatment Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Liver Fibrosis Treatment Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional integrated health system operating multiple hospital and clinic locations across a major United States metropolitan area, serving a large diagnosed diabetes and metabolic disease patient population. The health system reported annual operating revenue of approximately $1.6 billion (client-reported, unverified by MMA) and was evaluating whether to build a dedicated fibrosis screening and treatment referral pathway ahead of anticipated demand or delay the investment instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether building a dedicated non-invasive diagnostic and treatment referral pathway, which carried meaningful vendor and staffing investment cost, would generate sufficient early detection and treatment revenue benefits to justify the investment relative to continuing with existing ad hoc hepatology referral practices. Competing regional health systems were beginning to build similar pathways and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's referral pathway options against comparable health systems that had already implemented dedicated fibrosis screening programs, modeling patient identification impact and treatment revenue against implementation timing and vendor selection criteria. The analysis incorporated primary survey data from hepatology program directors at nine comparable regional health systems. Findings were cross-checked against identification benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Patient identification volume from the dedicated pathway exceeded management's initial projections once primary care and endocrinology referral integration was properly incorporated into the operational model used for this analysis.
  2. Peer health systems that built dedicated pathways early reported measurably stronger treatment initiation rates than health systems that waited for broader category standardization to force the decision.
  3. Referral pathway implementation costs were recovered faster than initially budgeted once downstream treatment revenue was properly incorporated into the financial model used for this specific program decision.
  4. Delaying pathway investment carried a quantifiable competitive risk as patients increasingly favored health systems offering coordinated, evidence-backed fibrosis screening and treatment access during provider selection decisions.
CLIENT PROFILE
The client is a mid-sized regional integrated health system operating multiple hospital and clinic locations across a major United States metropolitan area, serving a large diagnosed diabetes and metabolic disease patient population. The health system reported annual operating revenue of approximately $1.6 billion (client-reported, unverified by MMA) and was evaluating whether to build a dedicated fibrosis screening and treatment referral pathway ahead of anticipated demand or delay the investment instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether building a dedicated non-invasive diagnostic and treatment referral pathway, which carried meaningful vendor and staffing investment cost, would generate sufficient early detection and treatment revenue benefits to justify the investment relative to continuing with existing ad hoc hepatology referral practices. Competing regional health systems were beginning to build similar pathways and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's referral pathway options against comparable health systems that had already implemented dedicated fibrosis screening programs, modeling patient identification impact and treatment revenue against implementation timing and vendor selection criteria. The analysis incorporated primary survey data from hepatology program directors at nine comparable regional health systems. Findings were cross-checked against identification benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Patient identification volume from the dedicated pathway exceeded management's initial projections once primary care and endocrinology referral integration was properly incorporated into the operational model used for this analysis.
  2. Peer health systems that built dedicated pathways early reported measurably stronger treatment initiation rates than health systems that waited for broader category standardization to force the decision.
  3. Referral pathway implementation costs were recovered faster than initially budgeted once downstream treatment revenue was properly incorporated into the financial model used for this specific program decision.
  4. Delaying pathway investment carried a quantifiable competitive risk as patients increasingly favored health systems offering coordinated, evidence-backed fibrosis screening and treatment access during provider selection decisions.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 6): Select non-invasive diagnostic vendors and build coordinated primary care referral pathways ahead of full program rollout. Phase 2: Phase 2 (Months 7 to 15): Complete full screening and treatment pathway rollout across the covered population while tracking identification and treatment performance closely. Phase 3: Phase 3 (Months 16 to 22): Expand program communication to capture broader patient retention and referral value once the rollout demonstrates measurable results.
OUTCOME
Within eighteen months of program launch, the client reported diagnosed patient identification improvement of approximately 34% (client-reported, unverified by MMA) among screened populations, exceeding initial projections meaningfully. Treatment initiation rates improved measurably (client-reported, unverified by MMA), and the health system now serves as a regional reference model for peer integrated care organizations.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Liver Fibrosis Treatment Market?

The liver fibrosis treatment market was valued at approximately $1.40 billion in 2025. Growth is driven primarily by the category's first regulatory approval and expanding GLP-1 fibrosis label investigation.

How large will the Liver Fibrosis Treatment Market be by 2036?

The market is forecast to reach approximately $7.44 billion by 2036, roughly 4.57 times its 2026 value as GLP-1 and FGF21 formats broaden globally. Growth reflects expanding GLP-1 and FGF21 mechanism approvals.

What is the CAGR for the Liver Fibrosis Treatment Market 2026 to 2036?

The market is forecast to grow at a 16.4% CAGR between 2026 and 2036. Bull and bear scenarios range from roughly 15.1% to 17.6% depending on approval pace and trial outcomes.

Which segment is growing fastest?

GLP-1 and GIP receptor agonist therapies are the fastest-growing segment at approximately 24.8% CAGR, roughly 1.51 times the overall market growth rate. FGF21 analog therapies follow as the second-fastest segment.

Who are the major companies in the Liver Fibrosis Treatment Market?

Leading companies include Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Akero Therapeutics, and 89bio, together holding an estimated 56% of global commercial revenue. Smaller clinical-stage developers make up the remaining share.

Which country is growing fastest?

China is the fastest-growing country at approximately 19.8% CAGR, driven by its exceptionally large metabolic disease patient population and accelerating regulatory interest. The United States still commands the largest overall share of commercial value.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Mechanism of Action

  • THR-Beta Agonist Therapies
  • FGF21 Analog Therapies
  • GLP-1/GIP Receptor Agonist Therapies
  • PPAR Agonist Therapies
  • Antifibrotic Small Molecule Therapies
  • Combination Regimen Therapies

By End-Use Care Setting

  • Academic Hepatology Centers
  • Community Hepatology Practices
  • Endocrinology and Primary Care Referral Channels
  • Hospital and Health System Deployment

By Commercial Dimension

  • Specialty Pharmacy Direct Dispensing
  • Payer and Health Plan Contract Sales
  • Patient Assistance Program Channels
  • Value-Based Outcomes-Linked Contracts

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The liver fibrosis treatment market covers pharmaceutical therapies used to treat, slow, or reverse liver fibrosis associated with metabolic dysfunction-associated steatohepatitis and related chronic liver conditions, including thyroid hormone receptor beta agonists, GLP-1 and GIP receptor agonists, FGF21 analogs, and antifibrotic small molecules. It spans regulatory-approved therapies and late-stage pipeline candidates sold or administered through specialty pharmacy and hepatology practice channels. Liver transplantation, unrelated viral hepatitis antiviral therapies, and general weight management products without demonstrated fibrosis benefit are excluded from this scope.
Quantitative Units
USD billions (current prices); treated patient volume in thousands where applicable
Segmentation Dimensions
By Mechanism of Action; By End-Use Care Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Madrigal Pharmaceuticals Inc., Novo Nordisk A/S, Eli Lilly and Company, Akero Therapeutics Inc., 89bio Inc., Boehringer Ingelheim GmbH, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Sagimet Biosciences Inc., Terns Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Inventiva S.A., NorthSea Therapeutics B.V., Zydus Lifesciences Limited, Astellas Pharma Inc., Regeneron Pharmaceuticals Inc.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-141
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Liver Fibrosis Treatment Market Report (2026 to 2036).

This report analyzes the global liver fibrosis treatment market, covering approved, late-stage pipeline, and combination therapy segments across all seven MMA-tracked global regions. It includes detailed market sizing and forecasts through 2036, competitive benchmarking of the top twenty companies across established and clinical-stage developers, and segment-level analysis of mechanism adoption. The report draws on MMA's primary survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025, supplemented by company disclosures and government health agency data. Buyers receive full access to regional data tables, competitive profiles, and strategic recommendations tailored to developers, health systems, and healthcare investors worldwide.
Full seven-region market sizing and forecast data
Competitive benchmarking of twenty profiled industry vendors
Segment-level analysis of mechanism adoption trends
Primary survey data from 3,800 global respondents
Expert interview insights from 47 hepatology specialists
Strategic recommendations for developers and health systems

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts